Efgartigimod alfa

艾加莫德α

Report date: 2026/05/20 20:02:01
First In Class

Base Information

Drug NameEfgartigimod alfa
Drug Alias NameEfgartigimod alfa-fcab艾加莫德阿尔法EfgartigimodEfgartigimod PH20Efgartigimod PH20 SC +[16] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment
Mechanisms of ActionIgG receptor FcRn large subunit p51 antagonists
TargetsIgG receptor FcRn large subunit p51
Therapy Area/IndicationsRejection of organ transplantationImmunoglobulin G4-Related DiseasePemphigus +[29] 
Global Approved IndicationsPurpura, Thrombocytopenic, IdiopathicMyasthenia Gravis
Approved Indications in ChinaMyasthenia Gravis
Original Approved Country/TerritoryUnited States
Original Approved Date2021/12/17
Country/TerritoryCzechiaBelgiumBulgaria +[59] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesArgenx Se
China Registration ClassN/A

Develop Information

Active CompaniesArgenx SeZai Lab LtdUniversity Of Minnesota +[12] 
Inactive CompaniesZai Lab Pty Ltd
Active IndicationsRejection of organ transplantationImmunoglobulin G4-Related DiseasePemphigus +[24] 
Inactive IndicationsTachycardiaNephrotic SyndromeGlomerulonephritis, Membranous +[5] 

Other Information

ATC CodeL04AA58
Related LinksWikipediaDrugBankKEGG